8-K: Neumora Therapeutics Faces Nasdaq Delisting Threat Due to Low Stock Price

Neumora Therapeutics received a notice from Nasdaq for non-compliance with the minimum bid price requirement, potentially leading to delisting.

Summary

• Neumora Therapeutics received a notice from Nasdaq on May 14, 2025, indicating non-compliance with the $1.00 minimum bid price requirement for continued listing.
• The company has 180 calendar days, until November 10, 2025, to regain compliance by maintaining a closing bid price of $1.00 or more for at least ten consecutive business days.
• If compliance is not achieved by November 10, 2025, Neumora may apply to transfer to The Nasdaq Capital Market, needing to meet other listing requirements.
• Failure to regain compliance could result in delisting, subject to appeal.
• Neumora is considering options, including a reverse stock split, with stockholder approval to be voted on at the Annual Meeting on May 28, 2025.
• The reverse stock split ratio would range from 1-for-5 to 1-for-30, determined by the Board.
• There is no guarantee that stockholders will approve the reverse stock split or that the company will regain compliance with Nasdaq listing requirements.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice from Nasdaq, indicating financial distress and uncertainty about the company's future.

Positives

• Neumora has the option to regain compliance by November 10, 2025.
• The company can apply to transfer to The Nasdaq Capital Market if it meets other listing requirements.
• A reverse stock split is being considered as a potential solution to increase the stock price.

Negatives

• Neumora is currently not in compliance with Nasdaq's minimum bid price requirement.
• Failure to regain compliance could result in delisting from The Nasdaq Global Select Market.
• There is no guarantee that stockholders will approve the reverse stock split.

Risks

• The company faces the risk of delisting from The Nasdaq Global Select Market if it cannot regain compliance with the minimum bid price requirement.
• Stockholder approval of the reverse stock split is not guaranteed.
• Even with a reverse stock split, there is no assurance that the company will meet other Nasdaq listing criteria.

Future Outlook

The company intends to monitor the closing bid price of its common stock and consider options to resolve the noncompliance, including a reverse stock split, to maintain its listing on The Nasdaq Global Select Market.

Industry Context

Many biotech companies, especially those in the clinical stage, face volatility in their stock prices. Maintaining Nasdaq listing compliance is crucial for investor confidence and access to capital. Reverse stock splits are a common strategy employed by companies in this situation.

Comparison to Industry Standards

• Many companies facing similar situations, such as delisting warnings, consider reverse stock splits.
• For example, companies like Cassava Sciences and Ocugen have previously used reverse stock splits to maintain Nasdaq listing compliance.
• The success of a reverse stock split depends on the company's ability to improve its underlying business performance and investor sentiment.

Stakeholder Impact

• Shareholders face the risk of further stock price decline and potential delisting.
• Employees may experience uncertainty due to the company's financial situation.
• The company's ability to raise capital and fund its research and development programs could be affected.

Next Steps

• Neumora will monitor its stock price.
• Neumora will consider options to resolve the noncompliance.
• Neumora will seek stockholder approval for a reverse stock split at the Annual Meeting on May 28, 2025.

Key Dates

Keywords

Nasdaq, delisting, minimum bid price, compliance, reverse stock split, Neumora Therapeutics, stockholders, listing requirements